Benefits
GABA production in the gut (laboratory and animal finding)
Most B. adolescentis strains make GABA in laboratory tests. In rats, two strains (PRL2019, HD17T2H) raised fecal GABA relative to baseline, but so did a strain without the GABA genes, and absolute fecal GABA did not differ significantly from untreated rats. This has not been shown to ease anxiety or lift mood in people: GABA crosses the blood-brain barrier poorly, the same limit that applies to GABA supplements. Stool data from children found more B. adolescentis in those with mild anxiety and depression symptoms than in others, which argues against a simple protective link.
Longer measured sleep, mostly light sleep, with strain SBT2786
In one 4-week trial of 126 Japanese adults unhappy with their sleep, SBT2786 lengthened EEG-measured total sleep time versus placebo, mostly light sleep, but participants did not rate their sleep as better on two questionnaires. In a subgroup with higher salivary stress markers, sleep time and sleepiness on waking improved. The trial was run by the strain's maker and has not been repeated; it says nothing about other strains.
Mood: one secondary result with strain SBT2786
The only human mood result for a single B. adolescentis strain is a secondary outcome in the SBT2786 sleep trial: total mood disturbance on the POMS2 questionnaire improved versus placebo, while salivary stress markers did not change. A two-strain product pairing B. adolescentis NK98 with Lactobacillus reuteri NK33 (NVP-1704) reduced depressive symptoms in 156 adults with mild symptoms, but that effect cannot be credited to the B. adolescentis strain. Anti-anxiety and antidepressant effects of the species itself have been shown only in mice and rats.
Digestive health: small trials of two strains
Strain PRL2019 (20 billion CFU daily for 12 weeks) brought complete IBS symptom remission in 53% of 36 children versus 19% on placebo. Strain iVS-1 taken daily for 2 weeks led to fewer overall daily digestive symptoms than placebo, with improvements in urgency and diarrhea, in 21 adults who digest lactose poorly; in an earlier 3-week trial in obese adults it modestly improved a urine test of colonic permeability, a laboratory marker rather than a symptom. Both iVS-1 trials involved the strain's developers. Neither symptom result has been repeated, and neither shows a benefit for healthy adults.
Cognition: not tested in people for this species
No human trial of B. adolescentis alone has measured memory, thinking or any outcome in a neurodegenerative disease. The 2025 systematic review of bifidobacteria in neurodegenerative disease (Reiriz and colleagues) covered B. infantis and B. breve, not B. adolescentis. Laboratory and animal findings on inflammation do not show a benefit for thinking in people.
Mechanism of action
GABA production via glutamate decarboxylase pathway
B. adolescentis is one of the leading bacterial GABA producers in the human gut, expressing glutamate decarboxylase (GAD) enzymes that convert dietary glutamate into GABA. In a 2020 analysis of 1,022 bifidobacterial genomes, 94% of the 50 B. adolescentis genomes carried the genes for making GABA, and 79% of 82 strains tested in the laboratory converted glutamate to GABA; PRL2019 and HD17T2H were among the high producers. In a 5-day rat study, fecal GABA rose from baseline with these strains but also with a strain lacking the GABA genes, and absolute fecal GABA did not differ significantly from untreated rats. An effect of gut-made GABA on the brain has not been shown in people: GABA crosses the blood-brain barrier poorly, and vagus-nerve signalling is a hypothesis from animal work.
Proposed gut-brain signaling (animal studies only)
The proposed gut-brain pathways (GABA production, vagus-nerve signalling, effects on the HPA stress-hormone axis, and reduced NF-κB inflammatory signalling) come from mouse and rat studies. In people, the stool-metagenome data in Duranti 2020 found more B. adolescentis, not less, in children with mild (subclinical) anxiety and depression symptoms than in other children. That association cannot show cause in either direction.
Short-chain fatty acids and immune effects (laboratory and animal data)
Beyond gut-brain effects, B. adolescentis produces short-chain fatty acids (acetate, lactate) and modulates intestinal immune responses. Immune and metabolic effects have been reported in cell and animal studies. In people, a 3-week trial of strain iVS-1 in obese adults found no change in blood markers of endotoxin exposure, and no human trial of a single B. adolescentis strain has measured a metabolic or cognitive outcome.
Clinical trials
Randomized, double-blind, placebo-controlled trial, 4 weeks, capsules supplying over 100 billion SBT2786 cells daily (the authors note the number still alive was unclear). Primary outcomes: home EEG sleep measures and the OSA-MA sleep questionnaire; secondary: PSQI-J, Epworth sleepiness, POMS2 mood, salivary amylase. Nutrients 2024.
140 healthy Japanese adults aged 30 to 59 who were dissatisfied with their sleep were randomized; 126 were analyzed (61 SBT2786, 65 placebo).
EEG total sleep time rose compared with placebo, mainly as light sleep, along with more REM sleep and more time awake. Subjective sleep quality (OSA-MA, PSQI-J), daytime sleepiness and salivary stress markers did not differ from placebo. Mood (POMS2 total mood disturbance) improved as a secondary outcome. In a subgroup of 55 with above-average salivary amylase, sleep time and sleepiness on waking improved. One manufacturer-run trial of one strain, not replicated.
Genome analysis of 1,022 bifidobacterial strains, laboratory GABA tests on 82 B. adolescentis strains, a search of public stool-metagenome data, and a 5-day feeding study in rats. Scientific Reports 2020.
No human participants: bacterial genomes, laboratory cultures and Groningen rats (plus existing stool data from children).
94% of B. adolescentis genomes carried the GABA-making genes and 79% of tested strains made GABA; PRL2019 and HD17T2H were selected as high producers. Fed to rats for 5 days, both raised fecal GABA relative to baseline, but so did a strain lacking the genes, and absolute fecal GABA did not differ significantly between groups. In existing stool data, children with mild anxiety and depression symptoms carried more B. adolescentis than other children. No brain, mood, sleep or human outcome was tested.
Multicentre, randomized, double-blind, placebo-controlled trial in Italy: one stick of 20 billion CFU B. adolescentis PRL2019 (Gabapral) or placebo daily for 12 weeks. Outcomes: IBS symptom severity, pain and daily-life interference scores, stool form. Microorganisms 2025; authors declared no conflicts.
72 children with IBS diagnosed by Rome IV criteria, mean age 12 (36 per group).
Complete symptom remission: 52.8% (19/36) on PRL2019 versus 19.4% (7/36) on placebo. Symptom scores fell significantly in both groups; compared between groups, overall severity and pain scores fell more with PRL2019 at weeks 8 and 12. Normal stool form became more common, mainly in the constipation subtype. No adverse events in either group. One trial, in children with IBS; adults and healthy people were not studied.